| First Author | Allison J | Year | 2000 |
| Journal | Int Immunol | Volume | 12 |
| Issue | 1 | Pages | 9-17 |
| PubMed ID | 10607745 | Mgi Jnum | J:164342 |
| Mgi Id | MGI:4831115 | Doi | 10.1093/intimm/12.1.9 |
| Citation | Allison J, et al. (2000) Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction. Int Immunol 12(1):9-17 |
| abstractText | Insulin-dependent diabetes mellitus results when > 90% of the insulin-producing beta cells in the pancreatic islets are killed as a result of autoimmune attack by T cells. During the progression to diabetes, islet beta cells die as a result of different insults from the immune system. Agents such as perforin and granzymes, CD95 ligand and tumor necrosis factor-alpha, or cytokines and free-radicals have all been shown to cause beta cell apoptosis. The anti-apoptotic protein, Bcl-2, might protect against some of these stimuli. We have therefore generated transgenic mice expressing human Bcl-2 in their islet beta cells. Although Bcl-2 was able to prevent apoptosis induced by cytotoxic agents against beta cells in vitro, Bcl-2 alone could not prevent or ameliorate cytotoxic or autoimmune beta cell damage in vivo. |
